Abstract:Nishan Kunnummal Purayil, 1– 3 Vamanjore A Naushad, 1– 3 Prem Chandra, 4 Prakash Joseph, 1, 2 Zahida Khalil, 1, 2 Muhammad Zahid, 1, 3 Godwin Wilson, 3, 5 Muhammed Kunhi Kayakkool, 1– 3 Basma Ayari, 1, 3 Sajid Chalihadan, 1 Emad Bashier I Elmagboul, 5 Sanjay H Doiphode 3, 5 1 General Internal Medicine Department, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar; 2 Clinical Department, College of Medicine-QU Health, Qatar University, Doha, Qatar; 3 Department of Clinical Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar; 4 Medical Research Center, Hamad Medical Corporation, Doha, Qatar; 5 Department of Microbiology, Hamad Medical Corporation, Doha, Qatar Correspondence: Nishan Kunnummal Purayil, General Internal Medicine Department, Hamad General Hospital, Post Box No-3050, Hamad Medical Corporation, Doha, Qatar, Tel +97455792180, Email Purpose: To study the association between proton pump inhibitor (PPI) use and the risk of urinary tract infection (UTI) caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL). Patients and Methods: A retrospective cross-sectional study was conducted between October 2018 and September 2019. Adults with ESBL-UTIs were compared to adults with UTIs caused by gram-negative bacteria (GNB) and those with UTIs caused by miscellaneous organisms. The association between ESBL infection and PPI use was assessed. Results: A total of 117 of 277 ESBL cases, 229 of 679 non-ESBL GNB controls, and 57 of 144 non-ESBL miscellaneous controls were exposed to PPIs within 3 months prior to admission. The univariate analysis indicated unadjusted odds ratio for PPI exposure with ESBL infection versus the GNB controls was 1.43 (95% CI 1.07– 1.90, P = 0.015) while the odds ratio for PPI exposure with ESBL infection versus miscellaneous organisms was 1.10 (95% CI 0.73– 1.67, P = 0.633) indicating positive association (PPI exposure increases risk of ESBL infection). Multivariate analysis revealed a positive association between ESBL infection and PPI use versus the GNB controls with an odds ratio of 1.74 (95% CI 0.91– 3.31). While Esomeprazole was positively associated with ESBL infection, particularly compared with the miscellaneous group (adjusted OR 1.35, 95% CI 0.47– 3.88), Lansoprazole was inversely associated (adjusted OR 0.48, 95% CI 0.18– 1.24 and adjusted OR 0.40, 95% CI 0.11– 1.41 for ESBL versus GNB controls and ESBL versus miscellaneous organisms, respectively). Conclusion: Exposure to PPIs in the preceding 3 months showed an association with increased risk of ESBL-UTI. While Esomeprazole showed a positive association, Lansoprazole had an inverse association for ESBL-UTI. Restricting the use of PPIs may be beneficial in the fight against antimicrobial resistance. Keywords: proton pump inhibitor, PPI, ESBL, extended-spectrum beta-lactamase, urinary tract infections Beta-lactamases are enzymes that cleave the beta-lactam ring and lead to the inactivation of antibiotics. The first plasmid-mediated beta-lactamase TEM-1 in gram-negative bacteria was discovered in Greece in the 1960s. 1 TEM-1 and TEM-2 are the most common beta-lactamases found in gram-negative bacteria such as Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenza (H.influenza) , and Neisseria gonorrhea . While TEM variants hydrolyze penicillins and narrow-spectrum cephalosporins, they are ineffective against higher-generation cephalosporins with an oxyimino side chain, such as cefotaxime, ceftriaxone, and cefepime. In later years, oxyimino cephalosporin-resistant Klebsiella ozaena strains, named SHV-2, were discovered in Germany. 2 These were called extended-spectrum beta-lactamases (ESBL) due to their increased spectrum of activity, particularly against the oxyimino cephalosporins. Another type of beta-lactamase, called CTX-M, has greater activity against cefotaxime and other oxyimino beta-lactams. More than 220 TEM, 190 SHV, and 160 varieties of CTX-M beta-lactamases have been described. 3,4 In 1984 and 1988, TEM-related ESBL-producing organisms were detected in France and the United States, respectively. 5 The activity of ESBLs against various oxyimino beta-lactam antibiotics varies. They are ineffective against cephamycins (cefoxitin, cefotetan, cefmetazole) and carbapenems (imipenem, meropenem, ertapenem). ESBL-producing Enterobacteriaceae infections have a global distribution, particularly in specimens from hospital settings. Infection is also increasingly reported in community settings. The prevalenc -Abstract Truncated-

Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort

Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study

Initial Treatment With Lansoprazole in Young Dyspeptic Patients With Negative Urea Breath Test Result: A Randomized Controlled Trial With 12-Month Follow-Up

A66 PROTON PUMP INHIBITORS AND THE RISK OF INFLAMMATORY BOWEL DISEASE: A REAL WORLD POPULATION-BASED COHORT STUDY

[Distribution of Helicobacter Pylori in Stomach Before and after the Administration of Lansoprazole].

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region

The Effects of Pantoprazole on Kidney Outcomes

Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

Association between regular proton pump inhibitors use and cardiovascular outcomes: A large prospective cohort study

The proton pump inhibitor, lansoprazole, prevents the development of non-traumatic osteonecrosis of the femoral head: an experimental and prospective clinical trial

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

A Comprehensive Review of Epidemiological and Mechanistic Evidence

Long-Term Intake of Proton-Pump Inhibitors Could Be Associated with an Increased Incidence of Liver Cancer in Women

Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-Blind, Randomised Trial.

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study

Longitudinal microbiome changes in children exposed to proton pump inhibitors

Efficacy of tegoprazan‐based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double‐blind, active‐controlled study

Association Between Proton Pump Inhibitor Use and Extended-Spectrum Beta-Lactamase Urinary Tract Infection in Adults: A Retrospective Study

Proton pump inhibitors: Understanding the associated risks and benefits of long-term use.

Individualized prevention of proton pump inhibitor related adverse events by risk stratification